Cancer Immunotherapies: Biology, Therapeutic Approaches, and Immune Related Safety Assessments

Dates: April 9-10, 2019

Location: Genentech, South San Francisco, CA

DRAFT AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 8:30 AM – 9:00 AM | Introduction and overview                                                | • Objectives of the course/Goals over the 2 day course  
|               |                                                                         | • Brief overview of the various topics/modules that will be covered  |
| 9:00 AM – 10:00 AM  | General concepts of interplay between tumors and immunity               | Keith Bajhat, Pfizer                            |
| 10:00 – 10:15 AM   | Break                                                                  |                                                |
| 10:15 AM – 11:15 AM| The immune system in the tumor microenvironment vs. normal tissue      | Shannon Turley, Genentech                       |
| 11:15 AM – 12:15 PM | Immunotherapy platforms/modalities overview                             | Keith Bajhat, Pfizer                            |
| 12:15 PM – 1:15 PM | Lunch                                                                   |                                                |
| 1:15 PM – 2:15 PM  | Regulatory perspective on key cancer immunotherapy related toxicities  | Whitney Helms, US FDA                           |
| 2:15 PM – 3:15 PM  | Overview: toxicity as a result of immunomodulation                      | Rafael Ponce, Spark Therapeutics                |
| 3:15 PM – 3:30 PM  | Break                                                                   |                                                |
| 3:30 PM – 5:00 PM  | Toxicities associated with modulation of the innate immunity            | Tracey Papenfuss, Charles River Labs            |
Day 2: 10 April 2019

Toxicities associated with activation of the adaptive immunity

8:30 AM – 9:15 AM  Cytokine release syndrome  
                       Hervé Lebrec, Amgen

9:15 AM – 10:00 AM  Vascular leak syndrome  
                       Jule Gust, Seattle Children’s Hospital

10:00 AM – 10:15 AM  Break

10:15 AM – 11:00 PM  Neurotoxicity  
                       Conrad Liles, U. of Washington

11:00 AM – 11:45 PM  Cardiovascular and respiratory toxicities  
                       Rafael Ponce, Spark Therapeutics

11:45 PM – 12:30 PM  Lunch

Session 3: Toxicities associated with blockade of immunosuppressive/check point mechanisms

12:30 PM – 1:30 PM  CPI-induced immune related adverse events / autoimmunity  
                       Isabella Glitza-Oliva, MD Anderson

1:30 PM – 2:15 PM  CPI-related pregnancy risks  
                       Curtis Maier, GlaxoSmithKline

2:15 PM – 2:30 PM  Break

2:30 PM – 3:30 PM  Case-studies: Toxicities associated with blockage of negative regulators of T cells  
                       Rod Prell, Genentech  
                       Marc Pallardy, University of Paris, Sud

3:30 PM – 4:30 PM  Toxicities associated with synergistic pathways/ computational toxicology modeling  
                       Valeriu Damian, GlaxoSmithKline  
                       Loveleena Bansal, GlaxoSmithKline